Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Trial designs likely to meet valid long-term Alzheimer's disease progression effects: learning from the past, preparing for the future.

Kemp AS, Grossberg GT, Romano SJ, Arnold DL, Ryan JM, Bullock R, Streiner DL.

Int J Alzheimers Dis. 2009 Dec 22;2009. pii: 949271. doi: 10.4061/2009/949271.

2.

Priorities for research consortia on Alzheimer's disease.

Gauthier S, Garcia A, Sano M, Robert P, Senanarong V, Woodward M, Brodaty H.

Alzheimers Dement. 2010 Jul;6(4):359-62. doi: 10.1016/j.jalz.2010.05.2017.

PMID:
20630416
3.

Alzheimer's disease: clinical trials and drug development.

Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M.

Lancet Neurol. 2010 Jul;9(7):702-16. doi: 10.1016/S1474-4422(10)70119-8. Review. Erratum in: Lancet Neurol. 2011 Jun;10(6):501.

PMID:
20610346
4.

Tarenflurbil: mechanisms and myths.

Sano M.

Arch Neurol. 2010 Jun;67(6):750-2. doi: 10.1001/archneurol.2010.94. No abstract available.

5.

Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.

Okonkwo OC, Alosco ML, Griffith HR, Mielke MM, Shaw LM, Trojanowski JQ, Tremont G; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2010 Jun;67(6):688-96. doi: 10.1001/archneurol.2010.118.

6.

Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.

Reiman EM, Langbaum JB, Tariot PN.

Biomark Med. 2010 Feb;4(1):3-14. doi: 10.2217/bmm.09.91. Review.

7.

2010 Alzheimer's disease facts and figures.

Alzheimer's Association.

Alzheimers Dement. 2010 Mar;6(2):158-94. doi: 10.1016/j.jalz.2010.01.009.

PMID:
20298981
8.

Predicting progression of Alzheimer's disease.

Doody RS, Pavlik V, Massman P, Rountree S, Darby E, Chan W.

Alzheimers Res Ther. 2010 Feb 23;2(1):2. doi: 10.1186/alzrt25.

9.

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ.

Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6.

10.

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW.

Neurology. 2010 Jan 19;74(3):201-9. doi: 10.1212/WNL.0b013e3181cb3e25. Epub 2009 Dec 30.

11.

Predicting the time of conversion to MCI in the elderly: role of verbal expression and learning.

Oulhaj A, Wilcock GK, Smith AD, de Jager CA.

Neurology. 2009 Nov 3;73(18):1436-42. doi: 10.1212/WNL.0b013e3181c0665f. Epub 2009 Sep 30.

12.

Current Alzheimer's disease clinical trials: methods and placebo outcomes.

Schneider LS, Sano M.

Alzheimers Dement. 2009 Sep;5(5):388-97. doi: 10.1016/j.jalz.2009.07.038.

13.

Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.

Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Curr Alzheimer Res. 2009 Aug;6(4):347-61.

14.

Alzheimer's disease therapeutic research: the path forward.

Aisen PS.

Alzheimers Res Ther. 2009 Jul 9;1(1):2. doi: 10.1186/alzrt2.

15.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.

JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.

PMID:
19622817
16.

Body mass index and cognitive decline in mild cognitive impairment.

Cronk BB, Johnson DK, Burns JM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):126-30. doi: 10.1097/WAD.0b013e3181a6bf3f.

17.

Midlife and late-life obesity and the risk of dementia: cardiovascular health study.

Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES, Longstreth WT Jr, Luchsinger JA.

Arch Neurol. 2009 Mar;66(3):336-42. doi: 10.1001/archneurol.2008.582.

18.

Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake.

Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC.

Arch Neurol. 2008 Nov;65(11):1467-71. doi: 10.1001/archneur.65.11.1467.

19.

Amyloid-beta immunisation for Alzheimer's disease.

Wisniewski T, Konietzko U.

Lancet Neurol. 2008 Sep;7(9):805-11. doi: 10.1016/S1474-4422(08)70170-4. Epub 2008 Jul 28. Review.

20.

Endpoints for trials in Alzheimer's disease: a European task force consensus.

Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G; European Task Force Group.

Lancet Neurol. 2008 May;7(5):436-50. doi: 10.1016/S1474-4422(08)70087-5. Review. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
18420157

Supplemental Content

Support Center